Lew Woojin, Pai Madhukar, Oxlade Olivia, Martin Daniel, Menzies Dick
Montreal Chest Institute, McGill University, Montreal, Quebec, Canada.
Ann Intern Med. 2008 Jul 15;149(2):123-34. doi: 10.7326/0003-4819-149-2-200807150-00008.
Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility.
To perform a systematic review and meta-analysis of the effect of initial drug resistance and treatment regimen on tuberculosis treatment outcomes.
PubMed, the Cochrane Central Database of Clinical Trials, and EMBASE were searched for studies published in English from 1965 to June 2007. Additional studies were identified from cited references.
Randomized, controlled trials and cohort studies of standardized treatment of previously untreated patients with culture-confirmed pulmonary tuberculosis. Drug-susceptibility testing was done on pretreatment isolates from all patients and from patients with treatment failure or relapse.
Two authors reviewed the studies for methods, initial drug resistance, treatment regimens, and outcomes.
Pooled cumulative incidences were computed with random-effects meta-analyses. Association between risk factors and outcomes were determined by using stratified analyses. The cumulative incidence of acquired drug resistance with initially pan-sensitive strains was 0.8% (95% CI, 0.5% to 1.0%) compared with 6% (CI, 4% to 8%) with initially single drug-resistant strains and 14% (CI, 9% to 20%) with initially polydrug-resistant strains. Failure and relapse were most strongly associated with initial drug resistance. Failure was also associated with shorter duration of rifampin therapy and nonuse of streptomycin, whereas the rate of relapse was higher with shorter duration of rifampin therapy and nonuse of pyrazinamide.
Few studies included HIV-infected persons, and treatment outcomes were pooled despite considerable heterogeneity.
Treatment outcomes were substantially worse in the presence of initial drug resistance, which has important implications in resource-limited settings in which drug resistance is prevalent.
尽管耐多药结核病的患病率不断上升,但大多数低收入和中等收入国家仍使用标准化治疗方案,而未进行药敏评估。
对初始耐药性和治疗方案对结核病治疗结果的影响进行系统评价和荟萃分析。
检索了PubMed、Cochrane临床试验中心数据库和EMBASE,以查找1965年至2007年6月发表的英文研究。从引用的参考文献中识别出其他研究。
对既往未经治疗的痰涂片阳性肺结核患者进行标准化治疗的随机对照试验和队列研究。对所有患者以及治疗失败或复发患者的治疗前分离株进行药敏试验。
两名作者对研究的方法、初始耐药性、治疗方案和结果进行了审查。
采用随机效应荟萃分析计算合并累积发病率。通过分层分析确定危险因素与结果之间的关联。初始全敏感菌株获得性耐药的累积发病率为0.8%(95%CI,0.5%至1.0%),而初始单耐药菌株为6%(CI,4%至8%),初始多耐药菌株为14%(CI,9%至20%)。治疗失败和复发与初始耐药性密切相关。治疗失败还与利福平治疗时间较短和未使用链霉素有关,而复发率在利福平治疗时间较短和未使用吡嗪酰胺时较高。
很少有研究纳入艾滋病毒感染者,尽管存在相当大的异质性,但仍对治疗结果进行了汇总。
初始耐药情况下的治疗结果明显更差,这在耐药普遍的资源有限环境中具有重要意义。